Table 3 Everolimus blood concentration at the time of discontinuation or dose reduction by adverse events
Patient number | Number of measurements | Everolimus blood concentration, Mean ± SD (ng/mL) | Discontinuation or dose reduction by adverse events | |||
|---|---|---|---|---|---|---|
Discontinuation or dose reduction | Date (day) | Everolimus blood concentration (ng/mL) | Adverse events | |||
Pat.1 | 22 | 11.2 ± 4.6 |  |  |  |  |
Pat.2 | 9 | 16.4 ± 6.2 | Discontinuation | 147 | 17.5 | AST (G2), ALT (G2), ALP (G2), Hyperglycemia (G2), Mucosal inflammation (G2), Fatigue (G2), |
Pneumonitis (G1), Diarrhea (G1), Leukopenia (G1), Neutropenia (G1) | ||||||
Pat.3 | 2 | 13.1 ± 0.6 | Discontinuation | 26 | 12.5 | Pneumonitis (G3), Mucosal inflammation (G2) |
Pat.4 | 4 | 27.9 ± 18.0 | Dose reduction | 15 | 58.4 | Hyperglycemia (G3), Hypoalbuminemia (G3), γ-GTP (G3), AST (G2), ALP (G2), ALP (G1) |
Discontinuation | 41 | 19.1 | AST (G1), ALT(G1), ALP(G1) | |||
Pat.5 | 15 | 8.4 ± 2.5 |  |  |  |  |
Pat.6 | 3 | 10.2 ± 0.6 |  |  |  |  |
Pat.7 | 12 | 18.8 ± 4.8 | Discontinuation | 265 | 20.4 | Leukopenia (G3), Thrombocytopenia (G2) |
Pat.8 | 3 | 8.2 ± 0.5 |  |  |  |  |
Pat.9 | 4 | 27.6 ± 4.9 | Discontinuation | 98 | 35.4 | Pneumonitis (G3), Mucosal inflammation (G2) |
Pat.10 | 5 | 18.7 ± 1.3 | Dose reduction | 16 | 17.1 | Mucosal inflammation (G2), ALP (G1), Nausea (G1), Vomiting (G1) |
Discontinuation | 93 | 19.5 | ALP (G1), Nausea (G1) | |||